anticancer/headache

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 22 rezilta yo

Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In late 2019, an unidentified viral pneumonia was detected in Wuhan, China. Later, it was declared that it was pneumonia due to a new coronavirus. The World Health Organization (WHO) officially called it COVID-19 disease (Xie and Chen 2020). Ivermectin is a broad-spectrum antiparasitic agent,

Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Introduction Tumor treating fields (TTFields) are low-intensity (1-3 v/m) intermediate frequency (200 khz for GBM) alternating fields that disrupt cell division. The treatment is increasingly used as a supplementary modality for patients with glioblastoma (GBM). Recent randomized clinical studies

Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Brain tumors are the first cause of cancer mortality in children and the 3rd cause in young adults. The most frequent brain tumors are gliomas and among them the most common type is astrocytoma. The most malignant astrocytoma is Glioblastoma (GBM). Standard therapy of newly diagnosed GBM patients

Detection of (Sub)Clinical Toxicity in Irradiated vs. Non-irradiated Surgically Treated Esophageal Cancer Patients: a Pilot Study (CROSS SECT)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Radiation Necrosis: Stereotactic radiosurgery has become integral in treatment of brain tumors and arteriovenous malformations (AVM). In up to 10% of cases, this can lead to radiation necrosis (RN) with significant surrounding vasogenic edema and mass effect. Medical treatment for RN

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. Introduction to investigational treatment(s) and other study treatment(s) 1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in

The Effects of the Onion-Pumpkin Extract on Blood Pressure

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hypertension has become one of the most common diseases in the world and considered a public health challenge due to its association with morbidity and mortality and increased cost to society. Hypertension is the most important risk factor for cardiovascular diseases such as coronary heart disease,

Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The role of the proteasome in carcinogenesis and cell survival has been well established, and its inhibition associated with an accumulation of pro-apoptotic proteins and cell death. Proteasome inhibitors, such has bortezomib, have been extensively studied and are widely used as effective therapy in

Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hedgehog (Hh) pathway signaling may be important in prostate cancer progression and this pathway is upregulated in the castration-resistant state. More potent (maximal) castration achievable by CYP17 inhibition, using orteronel, may further upregulate Hh pathway activation. Itraconazole administered

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Colorectal cancer is the fourth commonest form of cancer worldwide and remains a leading malignancy both in incidence and mortality. Erbitux is an immunoglobulin G1 monoclonal antibody that specifically blocks ligand binding to the EGFR with high affinity, thereby preventing downstream signal

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patient population Phase I portion: Metastatic colorectal cancer. A total of 3 patients on each cohort. Additional 3 patients on the tolerable cohort. Total patient number: Minimum 6, Maximum: 12 Phase II portion: Metastatic colorectal cancer: A total of 33 patients will be treated in this portion.

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This is an open-label, single center, one-arm phase I dose-escalation study of dasatinib plus protracted , daily TMZ administered orally on a continuous daily dosing schedule among adult patients with recurrent or relapsing malignant glioma. The study format includes a classical "3+3" dose

Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Objectives of study are to determine activity of combo of Irinotecan + Temozolomide & to further characterize any toxicity associated w combo of Irinotecan + Temozolomide. Temozolomide administered orally at 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide administered on day 1

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Inclusion criteria: 1. Histological or cytological documented stage IV NSCLC. Sputum cytology alone is excluded. 2. Extracerebral lesions show stable disease after first line chemotherapy. Patient has recovered from CTCAE grade 3/4 toxicity. Patients who had never received EGFR-TKI or EGFR

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye